These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10026713)

  • 21. Characterization of human cytochrome P450 enzymes.
    Guengerich FP
    FASEB J; 1992 Jan; 6(2):745-8. PubMed ID: 1537465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.
    Davies SJ; Lennard MS; Ghahramani P; Pratt P; Robertson A; Potokar J
    J Psychopharmacol; 2007 Mar; 21(2):153-60. PubMed ID: 17329294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The cytochrome P-450 system].
    Spigset O
    Tidsskr Nor Laegeforen; 2001 Nov; 121(28):3296-8. PubMed ID: 11826461
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug essentials. The cytochrome P450 microenzyme system and targeted therapies: Minimizing drug interactions.
    Wilkes GM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl Nurse Ed):33, 52-6. PubMed ID: 19856586
    [No Abstract]   [Full Text] [Related]  

  • 26. Cytochrome P450: drug metabolism--why it's so important to understand.
    Byrd L; Luther C
    Geriatr Nurs; 2010; 31(5):385-7. PubMed ID: 20960692
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cytochrome p450 and their implication in chemotherapy].
    Delwaide PA
    Rev Med Liege; 1998 Nov; 53(11):700-10. PubMed ID: 9887664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs.
    Imai H; Kotegawa T; Ohashi K
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):409-11. PubMed ID: 22114850
    [No Abstract]   [Full Text] [Related]  

  • 29. [Features of the metabolism of various drugs involving cytochrome P-450 isoenzymes].
    Filimonova AA; Ziganshin AU; Ziganshina LE
    Eksp Klin Farmakol; 2007; 70(3):69-77. PubMed ID: 17650639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates on cytochrome P450-mediated cardiovascular drug interactions.
    Cheng JW; Frishman WH; Aronow WS
    Am J Ther; 2009; 16(2):155-63. PubMed ID: 19114873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New techniques in drug metabolism and clinical pharmacology/pharmacokinetics.
    Benet LZ
    Am Biotechnol Lab; 1993 Feb; 11(2):44-7. PubMed ID: 7763426
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.
    Murray M
    Drug Metab Rev; 1987; 18(1):55-81. PubMed ID: 3311684
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug interactions: Proteins, pumps, and P-450s.
    Shapiro LE; Shear NH
    J Am Acad Dermatol; 2002 Oct; 47(4):467-84; quiz 485-8. PubMed ID: 12271287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances: the cytochrome P450 enzymes.
    Slaughter RL; Edwards DJ
    Ann Pharmacother; 1995 Jun; 29(6):619-24. PubMed ID: 7663035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.
    Baneyx G; Fukushima Y; Parrott N
    Future Med Chem; 2012 Apr; 4(5):681-93. PubMed ID: 22458685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of in vitro human metabolism studies in drug development. An industrial perspective.
    Rodrigues AD
    Biochem Pharmacol; 1994 Dec; 48(12):2147-56. PubMed ID: 7811296
    [No Abstract]   [Full Text] [Related]  

  • 38. Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes.
    Hameed PN; Verspoor K; Kusljic S; Halgamuge S
    BMC Bioinformatics; 2017 Mar; 18(1):140. PubMed ID: 28249566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of drug metabolizing enzymes in the effect and side-effect of the drugs].
    Vereczkey L; Jemnitz K; Monostory K; Veres Z; Kóbori L
    Orv Hetil; 2005 May; 146(19):947-52. PubMed ID: 15969306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of drug metabolism: species differences and toxicological relevance.
    Graham MJ; Lake BG
    Toxicology; 2008 Dec; 254(3):184-91. PubMed ID: 18824059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.